Base on FDA feedback, CytoDyn (OTCQB:CYDY -1%) has filed a modified IND and protocol
with the agency for a Phase 2 clinical trial evaluating lead drug
leronlimab (PRO 140) in COVID-19 patients experiencing respiratory
complications.
The modified protocol calls for 75 participants
across up to 10 U.S. sites. The treatment window will be ~six weeks. The
study should start “in the very near future.”
The company says leronlimab inhibits (binds to) a
protein on the surface of certain immune cells called Cysteine-Cysteine
Chemokine Receptor 5 (CCR5) which plays a key role in modulating immune
cell trafficking in sites of inflammation such as the lungs of severely
ill patients infected with SARS-CoV-2.
https://seekingalpha.com/news/3552107-cytodyn-advancing-mid-stage-study-of-pro-140-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.